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 1 
INTRODUCTION 
 
Liver cancer is the second most common cause of death from cancer in the world with an estimated 780,000 
new cases and 742,000 deaths in 2012. It has a great geographic variation and is mainly prevalent in less 
developed regions, which are responsible for 83% of new cases. Out of all new HCC cases, China represents 
50% of them. Liver cancer is more common in men with a male-to-female ratio of 2,4. Areas with highest 
incidence (>20 new cases per 100,000 male inhabitants) of liver cancer include regions such as Eastern Asia 
(31.9) & South-Eastern Asia (22.2). In more developed regions, such as Northern America & most of 
Europe, male incidence is much lower at 9.3 and 4.6, respectively. Lowest incidence can be found in 
Northern Europe (4.6) and South-Central Asia (3.7)1. 
Since HCC is the predominant primary liver cancer in most countries, aforementioned geographical 
variations can be used as accurate reflections to the incidence of HCC1,2. HCC is the fifth most common 
cancer worldwide with an expected further increase in incidence the next following years2,4.  
 
HCC is a complex disease with a quite well known natural history, except for its early stages4. Majority of 
hepatocellular carcinoma occurs secondarily to chronic liver disease, most commonly liver cirrhosis. 
Cirrhosis of the liver is characterized by irreversible injury to hepatocytes and diminishing regenerative 
capacity of the liver resulting in fibrosis of liver tissue and destruction of hepatocytes, eventually leading to 
development of neoplastic changes5.  Known etiologies of cirrhosis & HCC include viral Hepatitis B, which 
is estimated to be responsible for at least 50% of cases worldwide, Hepatitis C for 25% and remaining part to 
be associated with other risk factors2,5,6. Such as alcoholic liver disease, intake of alfatoxin, nonalcoholic 
steatohepatitis, diabetes, obesity, high fructose intake, and hereditary hemochromatosis4,8,9. 
 
Due to the complexity of HCC, selection of treatment depends on several factors, such as extent of the 
disease, location, underlying liver function and general condition of the patient. All important for 
establishing the development and prognosis of the disease. A multidisciplinary team comprising, but not 
restricted to, of hepatologists, surgeons, oncologists, radiologists (including interventional), transplant 
surgeons and pathologists are all important in order to evaluate a certain treatment plan for patients with 
HCC. (3) 
Staging systems are essential to evaluate the prognostics of patients with HCC and to guide the therapeutic 
approach4,10,11. 
 
Curative therapies include surgical removal of the tumor lesion, liver transplantation & certain percutaneous 
ablative treatments. These therapies are aimed at patients who were diagnosed at an early stage of HCC. 
Patients with more advanced HCC are treated with minimally invasive therapies, systemic drugs or 
conservatively, which are aimed at improving quality of life and life expectancy (8). Unfortunately, due to its 
complex pathological course and late diagnosis, HCC still has a very poor prognosis (overall ratio of 
mortality to incidence is 0.95)1.  
 
In the last 30 years, much of the medical development and innovation in minimally invasive procedures that 
are used throughout the world today, are methods pioneered by interventional radiologists. The essential 
Seldinger technique introduced in year 19537, first embolization therapy in 1966 and further additional 
advances that lead to development of new ideas and technologies to treat various types of conditions. 
Important benefits notable with minimally invasive methods compared to open surgery include  
reduced postoperative pain, reduced trauma, shorter hospital stay and lower risk of infection.  
 
In this thesis we will explain various staging systems that are used to divide patients, cover treatment options 
that are available to patients with liver tumor, provide a detailed explanation of transarterial 
chemoembolization and other minimally invasive treatment modalities, and conclude with a discussion of the 
role of transarterial chemoembolization and other therapies in the battle of hepatocellular carcinoma & other 
liver tumors.   
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Diagnosis, Indications & Treatment 
It’s very important to divide patients into groups in order to provide the best possible care. This is crucial 
since patients are at a different stage of their disease and at a different level of health. In the treatment of 
hepatocellular carcinoma and other liver tumors, several classifications and guidelines have been developed 
throughout years to easily separate the growing number of patients. Although surgical resection or liver 
transplantation are one of the currently available curative treatments, approximately only 20-30% of the 
patients are viable for undergoing such complex procedures13-15. This review paper will mainly cover non-
invasive therapeutic modalities, which are suitable to the remaining patients. 
 
Diagnosis 
Imaging plays a key role in the diagnosis, and cirrhotic patients should be put under regular surveillance 
since 80% of new HCC cases arise in the setting of cirrhosis10. Recommendations from the European 
Association for the Study of the Liver (EASL) is to enroll cirrhotic patients, who wish to be treated for HCC, 
into a biannual surveillance program which includes an abdominal ultrasound examination and a sample to 
measure serum alfa-fetoprotein (AFP). A similar program is recommended by the American Association of 
the Study of Liver Diseases (AASLD). Upon discovery of a mass on ultrasound in cirrhotic patients (Figure 
1), EASL recommends nodules smaller than 1 cm to be closely followed up (3-4 months). If the mass is 
larger, between 1 and 2 cm, two samples of dynamic imaging techniques, such as contrast enhanced CT or 
MRI should be performed because they are able to detect a certain type of vascular pattern that is specific to 
hepatocellular carcinoma. This can be observed following rapid IV infusion of contrast. Computer 
tomography or MRI can detect differences in the uptake of contrast throughout liver tissue. Hepatocellular 
carcinoma is generally nourished by the hepatic artery and shows an increased uptake during the arterial 
phase (first 2-40 seconds), while the remaining normal liver parenchyma is enhanced during the venous 
phase (50-90 seconds after infusion)16. If imaging is unsuccessful or shows an atypical vascular pattern, a 
liver biopsy or cyto-histology needs to be performed. In cases of larger nodules (>2cm), one imaging 
technique with typical vascular presentation is sufficient, or an AFP level of >200 ng/ml (AASLD) or >400 
ng/ml (EASL) to diagnose HCC15,16. However in many facilities and institutions, histological evidence of 
HCC is required before extensive treatment15. Angiography as a diagnostic tool has been limited due to it’s 
poor detection rate of small tumors. PET scan has also limited use, and is mainly aimed to detect 
extrahepatic spread16.  
Figure 1. Diagnostic algorithm upon detection of liver mass in cirrhotic patient. Courtesy of European 
Association for the Study of the Liver23. 
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Staging Systems 
Staging systems are valuable tools to classify patients with cancer into groups. It’s meant to determine 
prognostic outcome, guide therapeutic approach and exchange information among researchers. With 
hepatocellular carcinoma and liver tumors there have always been problems in standardizing classifications 
and therapies accordingly. In response to this, several staging systems have been produced worldwide to find 
a solution. As previously mentioned HCC usually occurs in association with chronic liver disease and 
cirrhosis. The first staging systems we will review are concerned about underlying liver function and its 
correlation with survival after surgery. 
 
Child-Pugh score (Table 1) is one of the oldest methods used to asses the severity of chronic liver disease 
and cirrhosis. It’s a key component in many staging classifications today due to its simple and efficient 
grading system for liver function. Child-Pugh score is divided into Class A (5-6 points), B (7-9) and C (10-
15). Class A is associated with 100% 1-year survival rate, and B and C with 80% & 45%, respectively. Only 
patients with Child-Pugh Score A are available for surgical resection (52). 
 
Model for End Stage Liver Disease (MELD) was designed to predict short-term survival of patients 
undergoing liver transplantation. It takes into account the patients values for serum bilirubin, serum 
creatinine and the international normalized ratio for prothrombin time (INR) in the following formula: 
 
MELD Score = (0.957 * ln(Serum Cr) + 0.378 * ln(Serum Bilirubin) + 1.120 * ln(INR) + 0.643 ) * 10 
(if patient is on hemodialysis, value for Creatinine is automatically set to 4.0) 
 
The 3 month mortality rate in patients scored by MELD is 1.9% for a score of less than 9, 6% for 10-19, 
19,6% for 20-29, 52.6% for 30-39% and 71.3% for a score higher than 40.  
 
In order to assess the prognosis and possible curative treatment (surgical resection) for these patients, the 
Child-Pugh Score can be used in conjunction with MELD score. 
 
The following staging classifications are focused on liver tumors.  
 
  
Table 1 Child-Pugh Score 
Measure 1 Point 2 Points 3 Points 
Total Bilirubin (mg/dl) <2 2-3 >3 
Serum Albumin (g/dl) >3.5 2.8-3.5 <2.8 
PT INR <1.7 1.71-2.30 >2.30 
Ascites None Mild >Moderate 
H. Encephalopathy None Grade 1-2 Grade 3-4 
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Okuda System 
The Okuda classification system is one of the oldest systems focused on prognosis of HCC. It originates 
from 1985 17 and is based on four factors (Table 2). One parameter concerning the size of the tumor liver 
area involvement - more or less than 50%), and three related to liver status (ascites, albumin and bilirubin) 
(7). The classification is useful for end-stage patients due to its ability to stratify patients on advanced levels 
of HCC. Today with improved imaging and diagnostic technique, earlier diagnosis is more common and 
Okuda falls short in complete HCC staging due to its poor classification of early stage patients.  
 
Table 2 Okuda Staging 
Factors associated with 
advanced disease 
-Albumin level <3g/dL 
-Ascites 
-Bilirubin <3g/dL 
Tumor size > 50% of liver 
  
Stage 1 No factors present 
Stage 2 1-2 factors 
Stage 3 3-4 factors 
 
CLIP Score 
The Cancer of The Italian Program (Table 3) score was developed in 1998 from a retrospective analysis of 
435 patients  with HCC between 1990-1995. This staging system takes into account Child-Pugh Class, AFP 
level, tumor morphology (wether it’s unifocal & <50%, multifocal (<50%) or diffuse (>50%) and wether 
there is vascular invasion) and presence or absence of portal vein thrombosis. CLIP is designed mainly for 
advanced liver tumors, since it only discriminates tumor invasion of either more or less than half the liver. 
However CLIP was shown to be a good predictor of recurrence in hepatitis B patients with HCC who 
underwent curative resection 10,18,19.   
 
Table 3 Cancer of the Liver Italian Program 
Score 0 1 2 
Child-Pugh Stage A B C 
Tumor Morphology uninodular & extension < 
50% 
multinodular & 
extension <50% 
multinodular & 
extension > 50% 
AFP (ng/dL) <400 >400  
Portal vein thrombosis No Yes  
 
 
TNM Stage 
The conventional TNM staging system, which has been endorsed by the American Joint Committee on 
Cancer (AJCC), measures the primary tumor features (T) (Table 4), regional lymph nodes (N) (Table 5) and 
presence of distant metastasis (M) (Table 6). It’s main drawback was the lack of assessment of liver function, 
but newer revisions have included level of fibrosis and histological grade. In a review by S. Subramaniam et 
al from 2013 18, they state that TNM staging for HCC is unable to properly assess liver function, offer 
guidance on resectability and prognostic value of patients in advanced liver diseases.  
 
Japan Integrated System 
The Japan Integrated System (JIS) is a newer staging score system (Table 7), which was developed by the 
The Liver Cancer Study Group of Japan (LCSGJ) in 2003 20 to evaluate prognosis in patients of earlier stages 
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of HCC. This differs JIS from Okuda & CLIP, which are both unable to properly establish prognostic value 
in early-stage patients. JIS incorporates a modified LCSGJ-TNM staging system and Child-Pugh Score on a 
scored based from 0-10. It has been validated in Asian populations and shown to better assess prognostic 
values for early-stage patients than CLIP, but has not been validated nor gathered traction in Western 
population18.  
 
  
Table 5 Regional Lymph Nodes TNM Staging From AJCC 
NX Regional lymph nodes cannot be assessed. 
N0 No regional lymph node metastasis. 
N1 Regional lymph node metastasis. 
Table 6 Distant Metastasis TNM Staging. From AJCC 
M0 No distant metastasis. 
M1 Distant metastasis 
Table 7 Japan Integrated System  
Score 0 1 2 3 
Child-Pugh Stage A B C  
Stage by LCSGJ 1 2 3 IVA or IVB 
Table 4 Primary Tumor TNM, From American Joint Committee on Cancer (AJCC) 
Tx Primary tumor can not be assessed. 
T0 No evidence of primary tumor. 
T1 Solitary tumor without vascular invasion. 
T2 Solitary tumor with vascular invasion or multiple tumors none >5 
cm. 
T3a Multiple tumors >5 cm. 
T3b Single tumor or multiple tumors of any size involving a major 
branch of the portal vein or hepatic vein. 
T4 Tumor(s) with direct invasion of adjacent organs other than the 
gallbladder or with perforation of visceral peritoneum. 
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CUPI 
The Chinese University Prognostic Index (Table 8) was announced in 2002 from a retrospective analysis of 
929 patients, which were predominantly hepatitis B positive. It includes TNM staging, AFP level, Bilirubin 
level, Alkaline Phosphatase level, assessment of ascites and if patient was asymptomatic or not on disease 
presentation21. Comparison to CLIP & Okuda was made in the same study and concluded that CUPI showed 
better survival rate. However more recent studies 10,18 declare that CUPI shows questionable early prognostic 
values and wasn’t fully compatible in Western populations, with predominantly Hepatitis C patients.  
 
Table 8 Chinese University Prognostic Index  
TNM Stage  
1 & 2 −3 
3a & 3b −1 
4a & 4b 0 
Asymptomatic disease on presentation −4 
Ascites 3 
AFP > 500 ng/mL 2 
Total Bilirubin (umol/L):  
< 34 0 
34-51 3 
> 52 4 
ALP > 200 IU/L 3 
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Barcelona Clinic Liver Cancer Staging System 
The last staging system we will cover is The Barcelona Clinic Liver Cancer Staging System (BCLC) which 
is considered the standard scoring system for HCC staging (Figure 2). It was developed from a single 
institution and based from results of cohort and randomized control trial studies 15. BCLC has been endorsed 
by the American Association for the Study of Liver Disease (AALSD) & the European Association for the 
Study of Liver Disease (EASL) 18. Several studies have shown it to be the most comprehensive & applicable 
staging system for hepatocellular carcinoma 10, 18, 22, 23. BCLC staging system incorporates both prognostic 
and treatment indications, depending on what stage a patient is classified into. The 5 stages are divided into 
0,A,B,C & D from a set of factors, including Okuda Stage, Child-Pugh Score, performance status test (PST), 
bilirubin, portal hypertension, tumor nodules, and presence of vascular invasion/extrahepatic spread. PST 
translates into presence of cancer-related symptoms.  
Figure 2. Overview of Barcelona Clinic Liver Cancer staging system. Courtesy of European Association 
for the Study of the Liver23. 
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Treatment strategy based on BCLC 
 
Very Early Stage (0) & Early Stage (A) 
Stage 0 is defined in asymptomatic patients with a small single solitary nodule lesion (less than  2 cm) and  
with preserved liver function. Approximately 5-10% of patients in Western population are diagnosed at this 
stage, the figure is 3-5 times higher in Japan due to widespread implementation of surveillance programs23. 
Best possible treatment for patients in the earliest stage is surgical resection with 5-year survival rates around 
70% 15,24. Situations that preclude resection are the presence of portal vein thrombosis reflecting extensive 
disease, lymph node metastases, extrahepatic localizations and intrahepatic multiple, diffuse disease. When 
HCC arises in non-cirrhotic liver it is often diagnosed when the tumor becomes large and symptomatic. In 
the absence of diffuse disease involving both lobes or metastases, aggressive surgical management of HCC is 
indicated in non-cirrhotic liver. In these patients resection of the tumor may be considered no matter its size, 
since they are usually in good general condition and surgical resection usually involves the tumor mass 
rather than the functional parenchyma. 
 
Early Stage A group include patients with a single tumor lesion up to 5 cm or 3 nodules less than 3 cm each. 
They are also suitable for surgical resection as long as they have preserved liver function, but because 
cirrhosis affects majority of HCC patients and have a reduced liver function, liver transplantation is a more 
suitable option. Theoretically, the liver transplantation may cure the liver and cirrhosis at the same time. 
Studies show a 5 year survival rate of about 50% up to 70% in liver transplantation patients, unfortunately 
the biggest issue in this treatment modality is the prolonged waiting time 10,12,23. Patients who are not 
candidates for surgical resection can undergo local ablation treatment such as radiofrequency ablation & 
percutaneous ethanol injection. Both are covered in more detail in the following chapters. 
 
Intermediate Stage (B) 
Patients with compensated cirrhosis and HCC who do not fit the criteria of early stage, who have not yet 
presented cancer-related symptoms or vascular invasion or extrahepatic spread, correspond to the 
intermediate stage. Majority of this thesis will cover treatment options in this group and focus will be on 
transarterial chemoembolization. 
 
Advanced Stage (C) 
Patients in stage C present with cancer-related symptoms (PST) and with either extrahepatic spread (such as 
metastases or spread to lymph nodes) or vascular invasion. They have for a long time not been suitable for 
any radical therapies. By 2006 12 there was no convenient therapy for these patients. Recent studies with 
Sorafenib, an agent targeting tyrosine-kinase pathways, has provided hope for patients in this group and 
showed to increase median survival from 6 months to up to 14,7 in these patients23.   
 
Terminal Stage (D) 
The last stage in the Barcelona Clinic Liver Cancer staging system includes patients with Child-Pugh C & 
with poor physical health. They have a 1-year survival rate of around 10% and are candidates for supportive 
care15.  
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Radiofrequency Ablation 
The currently most used percutaneous thermoablative modality in the world is radiofrequency ablation 
(RFA). The last decade has seen a great expansion of this technique due to its impressive safety and efficacy.  
A radiofrequency ablation system consist of a set of 
probes and a generator. Older modalities included only 
monopolar probes and a grounding pad. Due to several 
drawbacks, including risk of electrical shock, skin marks, 
inability to ablate larger volumes and prolonged 
procedures, they were quickly replaced by newer and 
more advanced technologies (multipolar probes). 
Multipolar probes have multiple electrodes on a single 
probe, enabling a closed-loop circuit, rendering the 
grounding pad obsolete. 
RFA is a minimally invasive tool and as with other 
thermoablative methods, puts less stress on the patients, 
preserves more normal organ tissue and requires less 
hospital stay9,25. 
 
Probes are introduced into the target tissue with surgical, 
laparascopic or percutaneous access.  Radiofrequency 
ablation has mainly seen its use in selective solid tumors, 
particularly in liver, kidney, lungs and the musculoskeletal 
system9,25.  
 
Indications for RFA ablation in liver tumors applies to 
patients who are not candidates for surgical procedures, or 
have decreased liver capacity (e.g from cirrhosis). This 
includes HCC nodules less than 4 cm in size or even 
greater than 5 cm if the patient was previously treated 
with transarterial chemoembolization. For liver 
metastases, ablation is considered in lesions up to 4 cm (if 
fewer than 3) or up to 3 cm (if up to 4 lesions). Bigger 
tumors can be treated for palliative reasons.  
 
The procedure is performed in a sterile environment and 
the area of operation is surgically prepared. The patient is 
given general anesthesia or mild sedation. In mild 
sedation, the patient receives local anesthesia into the 
injection site for pain. When the equipment and staff are 
ready, the physician locates the tumor lesion with an 
imaging device, usually ultrasound, (Figure 4) and guides 
the probe inside the tumor tissue. 
Once introduction and deployment of the probe (Figure 3) 
inside the target tissue is complete, heating is delivered to 
the tissues through high flow of alternating current (375-
500 kHz) passing through the circuit. The tissue heating leads to protein denaturation that results in cellular 
breakdown and irreversible damage. As in figure 4, ultrasound probes are generally used to monitor the 
treatment. Echogenicity of the tissues imply formation of tissue and water vapor bubbles from the heated 
tissue, and can be used as an estimation of the ablation size. The temperature at the tip of the electrode is 
limited to 100ºC, since higher temperatures will produce charring of tissues and cells, which lead to an 
increased impedance (higher heat loss in peripheral tissues) within the target volume. Additionally, blood 
vessels near or within the target tissue are responsible for majority of the heat loss. This phenomena is 
labeled ”heat-sink effect” and is responsible for poor ablation in peripheral regions of the target volume 
9,25,26. Application of multiple probes enable the physician to treat larger tissue volume and achieve a more 
uniform heating pattern across the tumor tissue. 
 
 
Figure 3. Shows deployed radiofrequency ablative 
probes. With image guided assistance, probes are 
introduced into the target tissue. Once the probe is 
in the place, the tip is deployed in an umbrella type 
fashion (red arrow). The probe is ready for ablation. 
Figure 4. Careful application of RF probes with 
ultrasound guidance by Prof. B. Brkljacic at 
Radiology Dep. at University Hospital of Dubrava. 
Ultrasound allows precise placement of ablative 
probes and possibility to monitor therapeutical 
progress. 
 10 
 
Livraghi et al 27 showed that complications from radiofrequency ablation are uncommon, with major 
complications occurring at a rate of 3%. Most common are peritoneal hemorrhage, neoplastic seeding, 
intrahepatic seeding and intestinal perforation. Mortality rate at 0.3%.  
In order to decrease intraprocedural complications, careful selection of appropriate patients is mandatory. 
Exophytic tumors should be avoided to reduce the risk of neoplastic seeding and post procedural bleeding. 
Instead a transhepatic route should be taken to battle peripheral tumors 25. To avoid pneumothorax, puncture 
site should be as anterior and inferior as possible. And usage of prophylactic antibiotics to reduce the rate of 
intrahepatic abscesses in patients who are at a higher risk (biliary dilatations)25. 
 
RFA is a well known technology to control HCC lesions and liver metastases (Figure 5). It’s shown to be 
able to be used as a bridge therapy while waiting for transplantation28 and improve survival in patients with 
colorectal liver metastases29. In treatment of HCC, recurrence rate of RFA-ablated lesions is usually low 
(<10%), but recurrence of the cancer in other areas of the liver occurs more frequently (approx. 50%)9. In a 
prospective study conducted in Netherlands30 with 132 patients and 290 metastatic lesions ablated, median 
survival was 41 months, with a 3- and 5-year survival of 60% and 30.8%, respectively. More results are 
covered in the next section.  
 
RFA is a young and effective type of ablation that has gained the greatest marketshare in the world of 
thermoablative techniques due to its cheap, safe and efficient technology. It’s role in reducing cancer burden 
is already applied in several organs. With the advancements in imaging and use of adjuvant therapies 
(TACE, PEI etc), we will se an increase in indications and efficiency. 
  
A B 
C Figure 5. A 83 year old male with history of gastric 
cancer, was found to have a solitary metastasis of 
2.9x2.2x2.4cm in the liver. Pre-procedural CT (A) shows 
the mass (arrow), which was ablated under US-guidance 
under general anesthesia. Follow-up CT (B) which was 
done immediately after the procedure shows good tumor 
coverage. CT-scan 27 days later (C) reveals ablated mass 
and no recurrence or other emerging masses. 
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Percutaneous Ethanol Injection 
Percutaneous ethanol injection (PEI) is one of the oldest ablative techniques available on the market today. 
The principle of PEI is to enter the target tumor tissue through the skin with very thin needles (size 21-22 
gauge) and release ethanol. Releasing 96% alcohol directly into the tumor is used to reduce the burden from 
the tumor lesion and prolong survival rate. It’s been used widely for small HCC tumors because it’s cheap, 
easy-to-use, efficient & repeatable31.  
 
Patients indicated for percutaneous ethanol injection are not candidates for surgical resection or liver 
transplantation. They belong to stage A of BCLC staging system and have three or fewer than three tumor 
lesion, which are less than 3 cm in diameter and have well defined margins.  
Contraindications for PEI are patients with poor hepatic reserve, extrahepatic metastases, refractory ascites, 
coagulopathy (PT activity <35%, thrombocytes < 40 x 109/L), jaundice and portal vein tumor invasion. PEI 
has no restrictions on tumor location. 
The procedure can be performed on an outpatient basis with normal surgical precautions and local 
anesthesia. Tumor location is determined and a thin needle is guided into the tumor tissue with either 
ultrasound or computed tomography assistance (Figure 6A). When the needle is in place, ethanol is injected. 
The volume required to inject depends on the size of the lesion. With the formula V= 4/3x π (r+0.5)3 a tumor 
of 3 cm would provide an injection volume of approximately 32 ml32. At the radiology department of 
University Hospital of Dubrava, we don’t exceed injection volume of 15 ml per session. Main reason is to 
avoid major complications. Distribution of ethanol at absolute level (96%) within the tumor tissue leads to 
cellular dehydration and thrombosis of vascular beds resulting in destruction of tumor cells (Figure 6B). If 
performed well, one injection is sufficient to ablate the whole tumor volume. Usually PEI is performed twice 
a week for up to 4-6 weeks31. 
 
S. Shiina et al 32 conducted a multivariate analysis study in 2012, spanning over 20 years, with 685 primary 
hepatocellular carcinoma patients. They showed that PEI is a safe procedure with low rate of complications 
(2%). Minor complications include pain (located to injection site or abdomen), fever, alcoholic intoxication 
and elevated transaminase31. More serious complications include peritoneal bleeding, hemothorax, 
hemobilia, liver abscess, hepatic infarction, seeding of malignant cells and pleural effusion. Mortality rate 
was 0,06%. 
 
Recurrence of tumor lesions after PEI is a known issue. Approximately 50% reappear after 3 years, mostly 
within the liver31,32. Therefore it’s important to enroll the patient into a follow-up schedule every 3-4 months 
with CT or US in order to discover new tumor lesions.  
Figure 6. (A) A CT scan of a 67 year old male with cirrhotic liver show a hepatocellular carcinoma lesion (arrow). 
Dose of 30 ml ethanol was delivered in three injections to the tumor lesion over 8 days. (B) A control CT taken few 
days after the procedure shows tumor destruction. PEI can be repeated if viable tumor tissue is detected. 
A B 
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Survival rate in 5, 10 and 20 years after PEI procedure is 49.0%, 17.9% and 7.2% respectively32. Same study 
showed PEI to be comparable to surgical resection in survival rate, despite different indications between the 
treatments.  
Radiofrequency ablation (RFA), which shares its patient indication regime with PEI12,23, has been shown by 
randomized control studies33 to be superior to percutaneous ethanol injection irrespective of tumor size. 
Studies showed that overall 5 year survival rate of patients in the RFA and PEI groups were 55% and 42%, 
respectively. RCT by S. Shiina et al in 2005 34 showed patients treated with RFA to have a 4-year survival 
rate of 74%, compared to 57% in patients that underwent PEI. Length of hospitalization stay, amount of 
treatment sessions and mortality rate was also shown to be advantageous in patients from the RFA group. 
Conclusions from these studies is that radiofrequency ablation is superior to ethanol injection. 
 
Since the introduction of RFA, there has been a dramatic shift from PEI. Therefore PEI should only be 
performed in patients whom RFA can not be performed safely. This includes patients with enteric-biliary 
anastomosis (risk of developing liver abscess after RFA procedure), those which have adhesions between 
tumor lesion and GI tract (risk of RFA to produce GI perforation), or in cases in which RFA can’t be 
performed safely due to technical difficulties.  
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Transarterial Chemoembolization 
Transarterial chemoembolization (TACE) 
is a chemoablative therapy that has been 
used to treat unresectable HCC since the 
end of 1970s13. TACE is a percutaneous 
technique, which uses a coaxial catheter 
system to deliver several different types of 
anti-cancer and embolizing agents into the 
arterial network nourishing the tumor. 
TACE is based on the knowledge that the 
liver has a dual arterial blood supply, 75% 
provided by the portal vein and remaining 
25% by the hepatic artery, and that 
primary and secondary liver tumors 
almost exclusively receive their 
nourishment from the hepatic artery12,13,14. 
A detailed anatomical knowledge of 
normal and variant arterial structure of the 
liver is very important in order to 
effectively deliver the treatment and to 
spare non-target tissue. Based on this, it is 
possible to deliver chemo-therapeutic 
agents that will result in destruction of 
tumor parenchyma, while relatively 
sparing normal liver parenchyma. TACE 
is not deemed as a curative treatment for liver tumors, in fact it is used as palliative modality that has been 
shown to improve quality of life and prolong survival in patients13,14,35.  
 
Ideal candidates for transarterial chemoembolization belong to stage B of BCLC. These patients are 
asymptomatic with intermediate stage of HCC and preserved liver function. TACE should be avoided in 
patients with advanced liver disease and poor hepatic reserve (Child-Pugh Class C). Other contraindications 
include poor clotting test results (platelet count 50,000 mm3 or prothrombin activity <50%), renal or cardiac 
failure. If there is an insufficient or impaired collateral flow, in cases of hepatofugal flow, portosystemic 
shunt or portal vein thrombosis, patients should not be included because there will be a very high risk of 
necrosis of non-target tissue left without blood supply12,14,35. 
 
Patients are given fluid, anti-emetics, painkillers and antibiotics before and after the procedure. Hydration is 
a key element to avoid development of nephrotoxicity from the iodine contrast, tumor lysis and 
chemotherapeutic agents. Metronidazole is provided to avoid bacterial colonization in necrotic tumor tissue.  
A thorough angiographic examination (CT or MRI) has to be done beforehand to supply the physician with a 
clear map of the arterial network in the liver and of vessels feeding the tumor tissue. This includes 
angiograms of the hepatic artery proper and superior mesenteric artery to avoid missing any arterial 
variations. 
 
Patients are generally put under conscious sedation, and given local anesthesia into the right femoral area 
(Figure 7). With a coaxial catheter system, the right or left femoral artery is penetrated according to the 
Seldinger technique7, and a catheter is guided into the abdominal aorta, where iodine contrast is released to 
reveal the arterial network with fluorscopical guidance (Figure 8B). Then, arteries associated with the tumor 
are selected, and intra-arterial injection of chemotheurapeutic agents, usually enclosed within a carrier 
substance (lipiodol), and agents that obstruct hepatic artery blood flow is performed (Figure 8C). The idea is 
to deliver a very high local and concentrated dose of toxic agents into the blood flow, followed by 
embolization of tumor circulation in order to reduce washout of drugs, increase anti-tumor effect and to 
reduce the burden of systemic side effects13,14,35. 
 
 
Figure 7. The right groin is exposed and thoroughly cleaned before 
procedural treatment. The right femoral artery (arrow) is the entrance 
point for introduction of the catheter and tools used in TACE. On the 
left, instruments for PEI are in place for combination therapy with 
TACE. 
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Depending on the state of the patient and tumor advancement, multiple procedural sessions can be repeated 
in order to achieve a better tumor response. The interval between two TACE sessions should be between 4-
12 weeks36.  
Patients are usually provided with further hydration, antiemetics, painkillers and antibiotics after the 
procedure to reduce complications. The most common complication after a TACE treatment is the post-
embolization syndrome, it comprises of fever, nausea/vomiting and pain. Study by Lo et al in 2002 37 showed 
fever, pain and vomiting to be very common side-effects with an occurrence rate of 63%, 50% & 32%, 
respectively. In a risk factor analysis by Shi-Ying Wang et al from 2013 38, nausea and vomiting had an 
occurrence rate of 38% and 21%, respectively. The rising of temperature is not due to an infection, but due to 
tumor necrosis and therefore doesn’t indicate blood cultures to be taken. Post-embolisation syndrome starts 
to subside by 72 hours 39. Major side effects are rare 40, but include vascular complications, pulmonary 
embolization, severe infections, hepatic and renal failure. 
Figure 8. A, Fluorscopical image of hepatic artery before 
injection iodine contrast. B Outlining and arterial network 
of the tumor lesion is clearly visible after injection of 
iodine contrast. C, Approximately 10 minutes after 
TACE procedure. Shows severely decreased blood flow 
within the tumor lesion. D, Post-procedural CT image of 
the tumor lesion shows the lipiodol uptake from the 
procedure. E, Follow-up image of tumor lesion 10 
months later, shows a vast difference from the initial 
state.   
C 
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Agents used in TACE 
As discussed above, transarterial chemoembolization involves the intra-arterial administration of 
chemotherapeutic drugs mixed with embolizing agents. A systematic review of 175 randomized and cohort 
studies regarding the current practice and administration of transarterial therapy for hepatocellular carcinoma 
was conducted in 2007 by Marelli et al 36. It showed that several different chemotherapeutic agents are in use 
today, which of doxorubicin and cisplatin are the most common. Out of 61 chemoembolization studies, 36% 
used doxorubicin and 31% cisplatin. Other agents used as anticancer agents include epirubicin (12%), 
mitoxantrone (8%), mitomycin C (8%) and SMANCS (5%). SMANCS is a synthetic polymer of styrene 
maleic acid and neocarzinostatin 36. Criteria to determine the dosages of anticancer agents seem to be 
variable and not standardized. Some authors refer to a fixed dose, others use the patients body surface area, 
weight, tumor size or bilirubin level 36,41. Doses for the chemotherapeutic agents varied noticeably. A 
doxorubicin dose per session ranged from 25-50 mg, cisplatin 10-120 mg and epirubicin from 40 to100 mg. 
Even though administration of a single anticancer agent was the most common form of administration 
(75%), there was no evidence that showed double (15%) or triple therapy (6%) to be any more beneficial. 
Most importantly, no single anticancer drug was proven to be superior to any other drug 36. 
 
Lipiodol is an ethiodized oil that is frequently mixed with anticancer agents before a TACE procedure. This 
oily contrast medium was shown to remain in tumor tissue for several weeks to over a year after injection 
into the hepatic artery42, due to hypervascularization and absence of Kupffer cells, which are essential for 
lipiodol clearance, in tumor cells43. Before the procedure, lipiodol is vigorously mixed with anticancer agents 
in order to prepare an emulsion. The idea of lipiodol is to carry and localize drugs into tumor tissue, where 
the drug would be slowly released from the emulsion and remain in high concentration within the tumor 
tissue for an extended amount of time. It is however unclear how stable water-based agents (anticancer 
agents) combined with lipiodol, which is oil-based, are to deliver drugs slowly over time. In fact, it’s efficacy 
is unproven since there are no data that shows how slowly lipiodol is able to release anticancer agents into 
tumor tissue. Lipiodol can complicate the interpretation of residual vascularity of tumor tissue on post-
procedural CT imaging36.  
 
Embolizing agents are injected after administration of chemotheurapeutic agents. There are several types 
which are used in transarterial chemoembolization, including gelatin sponge, polyvinyl alcohol, steel coils, 
degradable starch microspheres, autologous blood clots, embospheres and drug-eluting beads. The most 
commonly used is gelatin sponge, which produces a temporary arterial occlusion with recanalization 
occurring after 2 weeks36. It can be prepared in several different sizes and forms, such as gelatin sponge 
particles, pellets, cubes, powder, fragments and strips. They have different sizes and are designed to reach 
different levels of the arterial system. Gelatin sponge powder has been abandoned, since it’s use has been 
shown to be harmful to extratumoral liver tissue, unlike other types, which have been shown to not be 
harmful to normal parenchyma36,41.  
Steel coils are equivalent to surgical ligation and occlude small to medium sized arteries. Together with 
polyvinyl alcohol and microspheres they are regarded as permanent embolic agents.  
 
Drug-eluting beads (DEB) is a drug-delivery system that can be used for TACE procedures. In fact, it 
combines the release of chemotherapy into target tissue with local embolization. 
DBE are microspheres made of biocompatible polymers, such as polyvinyl alcohol hydrogel, with an ion 
exchange mechanisms that allows binding to chemotherapy, such as doxorubicin. The beads are designed to 
occlude vasculature, causing embolization, and later deliver chemotherapy in a slower fashion than what is 
seen in conventional TACE procedure. This increases the drug-tumor tissue interaction and lowers the 
systemic concentrations, leading to a reduced number of complications. Early studies 44 show promising 
results, but further investigation is essential in order to define its role in TACE procedures. 
 
Lastly, embospheres are around 100-700 um in size and made of trisacryl gelatin microspheres. They have a 
smooth hydrophilic surface, which are able to penetrate deeper and embolize smaller and more peripheral 
vessels.  
 
To summarize, Marelli et al (2007) states in her study that there is no conclusion on which is the most 
effective embolizing agent on the market right now. Theoretically, embolizing agents with a standardized 
size that can be delivered into smaller arteries and cause permanent thrombosis should be more effective than 
gelatin sponge agents  
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Results of TACE 
To date, there has been a big number of randomized and non-randomized clinical studies of TACE. In the 
biggest and most comprehensive review of transarterial therapy of HCC36, in which 175 articles were 
covered, the most important conclusion was that quality of life and survival rate in patients increased after 
TACE treatment compared to conservative therapy. Same study states how clinical studies performed before 
year 2000 showed lower survival rate than compared to more recent ones, after 2000. The results for studies 
before 2000 showed 1,3 and 5 year survival rate to be 57 + 19%, 29 + 16% and 23 + 19%, and results after 
2000 to be 71 + 18%, 34 + 13% and 14 + 10%. This is likely to be a result of better procedural technique, 
better patient selection and better management of underlying liver disease. Eastern studies showed to have 
better 3 and 5 year survival rates (of 33 + 22 & 24 + 14) than the Western ones (27 + 9 and 7 + 10). 
Additional studies from other authors present similar results. Another RCT with 79 patients37, divided into 
one control group of 39 patients and remaining 40 into a group with chemoembolization, survival rate was 
significantly better in the chemoembolization group. The survival rate of 1,2 and 3 year was 57%, 31%, and 
26% for the chemoembolization group and 32%, 11%, and 3% for the control group. Study with 122 patients 
conducted by Llovet et al in 2006 11 showed that patients treated conservatively had a lower survival rate 
compared to patients treated with chemoembolization. The study presented a 1 and 2-year survival rate of 
82% and 63%, respectively for chemoembolization, and 63% and 27% for control group. More recent study 
from 2012 13 showed similar results, with a 3-year survival rate of 30-55% for patients that underwent 
TACE. These results pin the importance of TACE as a therapy modality in patients with unresectable HCC. 
Prognostic factors that are associated with the outcome include liver function, stage of cancer (number of 
tumor, nodules), vascular invasion and extrahepatic spread11,13,40,41. 
What’s important to remember is that TACE is not always used as the single therapeutic model in patients 
with liver tumors. They can often be combined with other treatments of what we have covered above. 
Common combination therapies include TACE with radiofrequency therapy, percutaneous ethanol injection, 
high-intensity frequency ultrasound, radiotherapy and three-dimensional conformal radiation therapy. In a 
meta-analysis performed by Liao M et al 45 covering 10 randomized trials and 18 observational studies (2497 
patients), they concluded that TACE combined with local treatments could improve overall survival rate 
compared to patients receiving TACE therapy alone. 
In a study with 71 patients from 2010 46, in which 26 received conventional TACE therapy and remaining 45 
underwent TACE with drug-eluting beads. Median survival from diagnosis of HCC in the group with TACE 
+ DEB were 610 (351–868) and 284 days (4 – 563) for TACE only group. This underlines clearly that there 
is further space and potential in development and understanding in the utilization of transarterial 
chemoembolization with other therapy modalities.  
Table 9. Overview of survival rate from standalone TACE procedure and combination therapies with TACE. Table 
used from Liao M, Huang J, Zhang T, Wu H (2013) 45 
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High-Intensity Focused Ultrasound 
High-intensity focus ultrasound (HIFU) is the only non-
invasive technology that we will cover in this paper. Unlike 
other interventional therapies used to treat tumors, such as 
radiofrequency ablation and chemoembolization, HIFU is 
regarded as a completely non-invasive technology,  since it 
doesn’t require any physical tools to be introduced into the 
patient in order to deliver energy.  
  Ultrasound modality in diagnostic setting work within ranges of 
sound waves that have no or minimal biological effect on the 
tissues 47. As acoustic waves travel through tissue, some of their 
energy gets absorbed and converted into heat. HIFU works by 
sending several waves to a common focus inside tissues, 
resulting in physiological and biological effects 48. The energy 
harvested from the collision of beams in the focus is capable of 
producing sufficient heat to produce tissue damage, such as the 
characteristic ”cigar-shape” in the focal 
zone (Figure 10). In the clinical setting, 
HIFU is available as an option in the 
treatment of tumors in prostate, uterus, 
breast, liver, pancreas and other. An 
important factor for efficient HIFU 
application is the distance between the 
target tissue and the ultrasound transducer 
(Figure 9). 
In the case of treating prostate cancer, 
the treatment can be delivered from a 
transrectal probe, resulting in a relatively 
short distance from the target organ. 
Prostate cancer has seen the most use of 
HIFU and some studies have shown results 
to be approaching surgical options, but no 
randomized control studies have been 
performed to date. In tumors of other 
organs, such as of breast, pancreas and 
liver, HIFU is primarily used as a bridging 
therapy for another treatment or as a palliative option48. HIFU is a new technology and more research has to 
be conducted in order to gather more information on long term effects, complications and success rate. 
 
High-intensity focused ultrasound treatment can be performed for inpatients, but also for outpatients. The 
patient is either put under general anesthesia or sedated with spinal anesthesia. Spinal anesthesia is 
recommended for patients undergoing treatment of prostate and uterine fibroids in order to remain 
comfortable and static throughout the procedure. Once the patient is in place, the transducer is placed 
properly to face the target tissue. It is introduced into the rectum in case of prostate cancer or applied directly 
on the skin when treating liver tumors. The US transducer is connected to a computer, which allows the 
physician to construct a treatment plan for the therapy. Depending on the tumor type, size and location, the 
procedure takes around 2-4 hours.  
 
Tumors are treated by destroying as much as possible of the tumor tissue. In focused ultrasound therapy, 
tissue damage is accomplished by several mechanisms, including thermal, mechanical and chemical. Tissue 
heating occurs as a result of the absorbed energy that is applied onto the focal zone. The amount of energy 
delivered is a function of the temperature the tissue is heated to and on how long the tissue is exposed to the 
ultrasound beams. This results in destruction of tumor tissue from coagulation necrosis. Hemostasis occurs 
as an indirect effect of the thermal injury, since the high temperature induce vessel collapse and subsequent 
formation of fibrin plug48. Cavitations are produced in tissues from very high-intensity acoustic waves, 
which are able to grow and have a very high temperature inside. Eventually these cavitations can implode, 
releasing a strong shock wave throughout the tissue and cause mechanical injury.  
Figure 9. Transrectal probe for HIFU 
therapy. Courtesy of Sonacare Medical. 
Fig 10. Characteristic shape of a thermal lesion, resembling a cigar, 
from focused ultrasound therapy. Performed on a porcine liver 
specimen. Granted permission from KJR (16) for use of the figure. 
 18 
 
Additional methods to produce 
biological effects include targeted drug 
/gene delivery therapy and 
thrombolysis. Targeted drug therapy is  
a novel type of therapy that involves 
the application of certain 
”microbubbles” (Figure 11), that are 
loaded with drugs or plasmid-DNA. 
These are injected into the 
bloodstream and travel as vehicles. 
The walls of the microbubbles are 
designed to rupture once they receive a 
set of sound waves with the correct 
level of intensity. Theoretically, if the 
ultrasound transducer aims its beams 
to a vessel feeding the tumor, passing 
microbubbles would burst and release 
a highly concentrated and localized 
dose of therapy. This has an advantage over systemwide genetic therapy, because it only delivers therapy to 
the diseased area and subsequently reduces side-effects48,49.  
 
Thrombolysis can be achieved and improved from ultrasound. By using low intensity acoustic waves, non-
thermal mechanisms such as acoustic cavitation open up cell membranes and allow thrombolytic agents to 
have a greater bioavailability and effect, potentially resolving a thrombus.  
 
Clearly HIFU has a big potential as a therapeutic modality for tumors and other diseases. Advantages include 
the non-invasiveness and low post-therapeutical pain for patients. Unfortunately with the current technology 
HIFU still comes with some limitations. Including difficulties operating on moving target organs, 
interference with gas in bowel or bony tissue, and the relatively high cost of technique in relation to its 
effectiveness. There’s great potential for HIFU in the future and in the field of interventional oncology. In 
regards to liver cancer, no randomized control trials have been performed that shows HIFU singlehandedly 
to be a reliable treatment option, but HIFU in combination with transarterial chemoembolization has been 
proven to prolong survival of patients with advanced hepatocellular carcinoma50.  
Figure 11. Schematic drawing of gene-delivery therapy. Sound waves of 
low intensity induces rupture of microbubbles, which lead to release of 
DNA. Granted permission from KJR (16) for use of the figure. 
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Cryoablation 
Cryoablation is a type of percutaneous ablation technique that is used to treat tumors and other diseases. 
Special type of probes are penetrated through the skin and introduced into the target tissue with the guidance 
of imaging devices such as ultrasound, computer tomography (CT) or magnetic resonance imaging (MRI). 
Cryoablation, also called cryotherapy, as the name implies, delivers subzero temperatures to tissues in order 
to cause local tissue ischemia. The freezing 
temperature is delivered to tissues through a set of 
small probes that are equipped with argon. When 
argon is exposed to very low pressure within the 
probes, it reaches temperatures of less than -100 
celsius & and produces an ice ball at the tip of the 
probe (Figure 12). Water molecules transform to 
solid state (ice) that results in cellular dehydration, 
which leads to rupture of cell membranes, vascular 
stasis and thrombosis. As a consequence, cells are 
destroyed and ravage of local tissue occurs.  
Previously, cryoablation, was only possible with 
laparoscopic or surgical access because older 
cryoablative tools were too large to penetrate the 
skin, but with advancements in probe technology & 
size, cryoablative procedures can be performed 
without surgical assistance51.  
 
Candidates for cryotherapy are patients with 
advanced liver disease, including metastatic lesions. 
They are not candidates for surgical resection, radiofrequency ablation or chemoembolization. Since 
cryotherapy is a new ablation technique, patients are generally enrolled into clinical studies that offer an 
alternative therapy. This includes patients with primary liver tumors, such as hepatocellular carcinoma, and 
liver metastases. Lesions larger than 5 cm are ideally avoided due to higher recurrence rate and decreased 
efficiency of therapy (18,19). Studies show that lesions below 3 cm are best treated. Main reason is believed 
to be due to absence of large vessels near the tumor tissue. One of the drawbacks of cryoablation is the 
possibility of local blood flow to prevent temperatures to reach lethal levels, so called ”thermal-sink effect”. 
This can lead to poor therapy outcome and increase the recurrence rate of tumor tissue51,52. 
Patients are put under general anesthesia and undergo normal surgical preparation. Depending on the facility, 
US, CT or MRI can be used to guide the cryoablative probes into the target tissue. Procedure can start once 
the probe is deemed to be in place. A set of two 15-minute freezing periods separated by a 10 minute break, 
is sufficient to reach tissue temperature of -20 and -50 celsius that will result in complete tissue destruction51. 
Certain cells are differently sensitive to the freezing temperature. Important resistive cells include collagen 
and elastin fibers, which are important parts of connective tissue. This fact maintains a certain safety profile 
of the procedure, since healthy tissue suffers less to the damaging effects of treatment.  
Figure 12. This picture shows activated cryoablative 
probes with an ice ball formation at the tip. Credit to 
author Servet Tatli et al 51 for the figure. 
Figure 13. Observation of an ice ball formation that 
cover the liver lesion. This is taken 
intraprocedurally.  
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The freezing can be observed during the treatment by US, CT  or MRI (Figure 13), but US is often avoided 
since posterior acoustic shadowing limits visualization51. This is an important difference from 
radiofrequency ablation which doesn’t allow intraprocedural monitoring.   
 
Complications that can occur within a cryotherapy procedure to liver lesions are rarely severe. Small 
intrahepatic hematomas can occur if tumor lesion is situated near any larger blood vessel. Postoperative pain 
is most often absent, but if present lasts around 1-2 hours. If a large volume of hepatic parenchyma is 
involved, possibility of severe myoglobinuria can occur, especially in a patient with poor renal function. 
Therefore it’s common to undertake precautionary prophylactic measures by maintaing adequate urinary 
output.  
 
Summary 
To conclude cryoablation, it’s an innovating technique that destroys tumor tissue by extremely low 
temperatures. Due to the application of probes into the organs, virtually any tumor shape can be targeted, and 
with individual control of pressure in probes, healthy tissue can be spared. This is a welcome addition as an 
alternative treatment for solid tumors that are not responding to systematic chemotherapy. Several clinical 
studies have been performed, but no randomized control trials are known to date23. Lastly, imaging 
techniques can be used intraprocedurally to maximize treatment of tumor and at the same time avoid serious 
complications.  
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Microwave Ablation 
Microwave ablation (MWA) is one of the latest developments in ablation techniques. Similar to 
previously percutaneous ablative techniques mentioned, it consists of a set of probes (Figure 14) that are 
introduced into the target tissue with either percutaneous, laparascopic or surgical access. Microwave probes 
are equipped with multiple antennas along the probe that emit electromagnetic waves. The antennas are 
capable of delivering radio waves between 0,9 and 2,4Ghz. Water molecules are polar and will interact 
heavily with radio waves of such energy53. This interaction leads to severe agitation and movement of water 
molecules, which flip back and forth 2-5 billion times a second, resulting in an increase of temperature in the 
target tissue54. Eventually, the tissue will lead to cellular death and coagulation necrosis from excessive 
heating. Majority of patients with hepatocellular carcinoma are not candidates for surgical resection and are 
therefore candidates for ablative therapies. As with other thermoablative techniques, MWA aims to control 
the level of tumor growth in nonresectable lesions. Even though radiofrequency ablation is the most widely 
used thermoablative technique in the world, it still comes with some drawbacks. Major ones include heat 
sink effect from blood vessels, high local recurrence rate in lesions above 3 cm and difficulties in ultrasound 
imaging of ablated lesions. Microwave technology has been shown to offer many benefits of RFA, but also 
some advantages. Studies have shown microwave ablation to produce higher intratumoral temperatures that 
result in larger and faster tumor ablations54,55. In the clinical setting MWA has been undergoing clinical 
studies in treatment of both primary and secondary liver, lung, renal and bone tumors. 
 
The patient undergoes routine surgical preparations with local anesthesia. Depending on the patients 
comorbidities and general condition, general anesthesia might be necessary. Unlike monopolar 
radiofrequency sets, microwave ablation does not require grounding pads. The lesion is located with imaging 
and the probe is inserted with surgical, laparascopic or percutaneous access. Procedural steps of microwave 
ablation therapy is similar to radiofrequency ablation, saving the physician from a steep learning curve 
generally associated with new therapies.  Lesions from MWA have been shown to have a much greater 
volume and be more effective around blood vessels than lesions by radiofrequency ablation in human (20) 
and porcine liver25. This results in a better clearance of unwanted tumor tissue and potentially better care for 
patients. In its current stage, microwave ablation is still in its infancy and far away from worldwide clinical 
application. It builds on microwave technology that is destined to improve some of RFA’s drawbacks. 
Current studies show improvements, but the technology needs additional time and research to develop into 
an additional solution for patients with cancer.  
Figure 14. The picture shows a 
microwave ablation probe. It’s equipped 
with antennas, which are able to emit 
high frequency radio waves. 
Temperature control is built-in into the 
probe, allowing the physician to protect 
itself and non target tissue. Courtesy of 
Microsulis Medical Limited. 
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Discussion 
It is clear to us now that interventional radiology is an important part of hepatocellular and liver tumor 
treatment. Advancements in technology and medicine has allowed new innovative treatments to take place 
and be part of the battle against horrible diseases. Hepatocellular carcinoma is one of the deadliest cancers in 
the world and due to its growing incidence, additional focus is necessary in order to save lives. We know that 
majority of HCC cases occur in patients with previous cirrhotic liver. It’s therefore of utmost importance to 
prevent diseases that can progress to cirrhosis. As with any other diseases in medicine, prevention is the most 
preferred, affordable and efficient way of treatment. Preventative measures for HCC include reduction of 
HBV/HCV transmission, promotion of vaccination of HBV, lifestyle changes preventing obesity and alcohol 
abuse and controlling metabolic diseases, such as diabetes. 
Fortunately there are several treatment options to patients with confirmed hepatocellular carcinoma or other 
liver tumors. Barcelona Clinic Liver Cancer staging system is the recommended tool for prognostic outcome 
and treatment allocation. In it, surgical resection and liver transplantation are deemed as potential curative 
treatments that are available to patients with solitary tumors and well preserved liver function. Studies have 
shown 5 year survival rate to be up to 70% and possibly even higher in certain clinics. Unfortunately, due to 
late diagnosis, this type of treatment only applies to approximately one fifth of patients with hepatocellular 
carcinoma. It was quite surprising to me that such a low number of patients are available for curative 
treatment. The low number can in some part be explained from the high incidence differences throughout the 
word. Majority of patients are from less developed regions with poor surveillance programs and primary 
health care. This is definitely a contributing factor that leads to a greater risk of missing patients with HCC in 
the early phase. Additionally, there is no simple and reliable tumor marker that can be used to scan massive 
populations for incidence; and HCC becomes only clinically difficult in advanced stages, resulting in patients 
searching for health care too late. 
 
Patients with HCC & impaired liver function can undergo radiofrequency ablation and percutaneous ethanol 
injection. These are minimally invasive treatments that can potentially cure and increase the survival rate of 
patients with HCC. The focus of this thesis has been transarterial chemoembolization, which combines 
transcatheter delivery of chemotherapeutic agents emulsified with lipiodol, followed by vascular 
embolization. My expectations of TACE were much greater than the medical literature has proven. The 
combination of drug delivery and simultaneous blockage of blood flow sounds very powerful, but to 
translate the procedure into medical practice seems to be more difficult. It requires a great amount of 
knowledge and skill to be able to master coaxial catheter systems and select specific arteries during 
fluoroscopic imaging. In my opinion, this is regarded as a disadvantage to TACE, since only physicians with 
years of experience in the field of interventional radiology have skills enough to attempt such a procedure. 
Hopefully, improvements in imaging techniques and other technological advances will allow for an easier 
and more efficient operative procedure in the future. Despite this, a great amount of work from physicians 
throughout the world have overcome the technological barriers of TACE and developed it into a reliable and 
powerful tool for treatment of liver tumors. There are several advantages of TACE that have lead to its 
adoption in many hospitals and clinical centers. The minimally invasive approach to access and deliver 
agents is fully accessible from a single perforation of a medium sized artery, such as the femoral artery. 
Through this site, the procedure can be completely performed, allowing the patient to avoid general 
anesthesia and its complications. Certain patients, depending on their previous clinical history, may however 
require general anesthesia. This type of minimally invasive approach drastically reduces pain, operative 
complications and hospitalization stay. Additionally, the procedure includes local injection of chemotherapy, 
instead of systemic, reducing symptoms from these drugs. Due to this, transarterial chemoembolization has 
the capability to encompass patients that are not suitable for surgical resection. This includes majority of 
tumor-positive patients, since a great number of them have an expected poor surgical outcome, e.g due to 
poor liver function, difficult tumor location, poor physical condition and old age; or have metastatic lesions 
in the liver. As mentioned in the result section of TACE, the procedure is proven by several RCTs to increase 
the survival rate and quality of life in patients, who otherwise would not be suitable for curative treatments. 
Several questions remain to be answered in order to develop and improve the outcome of chemoembolization 
in patients. First, which is the best chemotherapeutical drug? As previously mentioned36 no 
chemotherapeutic drug was proven to be more beneficial than any other. Doxorubicin is the most used drug 
worldwide, but in Japan epirubicin is predominant, mainly due to epirubicin being covered by the National 
Insurance System. My thoughts on the difficulties of the medical research to declare a single superior drug 
are multiple. Firstly, it seems to be unclear how much of the chemotherapy released into the bloodstream is 
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actually picked up and utilized within the tumor cells, leading to unexpected results. The difficulty of 
concentrating the agents within the tumor tissue is one of the disadvantages of TACE. 
Secondly, the matter of which is the best treatment scheme for full TACE treatment, whether it should be 
undertaken at a fixed time or on disease progression after initial response. Finally, what is the actual role of 
chemotherapy in TACE? Marelli et al36 showed in 2005 that patients receiving transarterial embolization 
(TACE without chemotherapy) or transarterial chemoembolization (TACE) presented with no difference in 
survival rate. Both presented with an improved survival rate and quality of life above conservative therapy, 
but failed to show any greater difference between each other. The study concluded that this statement could 
be changed in the future when a higher number of randomized control trials have been conducted. Fast-
forwarding several years later, the EASL45 guidelines from 2012 on treatment for HCC does not recommend 
bland embolization technique instead of TACE. My impression is that this question still remains unresolved, 
because multiple studies declare transarterial embolization to be more or less equivalent to TACE. I believe 
that a meta-analysis of great sample size is necessary to provide a definitive answer to this question.  
 
In regards to the second step of TACE, which is the embolization of the arterial network feeding the tumor 
tissue, some points need to be cleared out. Even though the hepatic artery, in majority of cases, is the major 
nourishing vessel for a liver tumor, it’s not the only one. There are collateral arteries in the surrounding liver 
parenchyma that deliver oxygenated blood to the tumor tissue. These smaller vessels, that are difficult to 
detect on imaging, are targets of embolizing agents that are delivered after injection of chemotherapy. Small 
particles, which have been designed to embolize arteries, are injected into the arterial network and travel in 
an emboli fashion in order to block blood flow. The behavior of the embolizing agents within the arterial 
network can not be controlled by the physician, leading to random dispersion of the agents. This uncertainty 
will carry a risk of certain tumor nourishing arteries to be left unblocked and subsequently spare tumor 
tissue. This is certainly one major reason to why there is a possibility of tumor recurrence after TACE 
treatment. More advanced tumors or metastatic lesions have a greater vascularity and produce a higher 
number of collateral arteries. Evidently recurrence rate is higher in these cases. On the positive note, TACE 
can be used to reduce and dampen the effect of larger tumor nodules in patients with very late stage of 
disease without putting to much restrain on the patient from the procedure.  
 
Lastly, TACEs main advantage is its ability to be fused with other treatment modalities, which we have 
covered in this thesis. This solution is practically reasonable since ablative therapies such as RFA, PEI, 
MWA, Cryoablation & HIFU access the liver from the abdomen, unlike TACE which is performed from the 
groin area. Liao M published a meta-analysis study45 with 2497 patients in 2013 that showed any treatment 
of the above combined with TACE to be more beneficial than taking TACE alone. Today, TACE +RFA or 
TACE+PEI combination are used most frequently as they have repeatedly been associated with improved 
survival rate than local therapies alone. The conclusion is reasonable, since the tumor lesion is locally 
attacked from two angles, primarily by toxicity and vascular deprivation from TACE and additionally from 
thermal ablation, which clears the remaining tumor tissue. 
 
Conclusion 
Transarterial chemoembolization is a minimally invasive treatment modality in the field of interventional 
radiology that is primarily used to treat liver tumors such as hepatocellular carcinoma and metastases from 
other tumors. TACE has been categorized as a treatment for patients in the intermediate stage of BCLC, who 
are not suitable for more radical therapies such as surgical resection and radiofrequency ablation. The 
principle of TACE involves the local injection of chemotherapy followed by embolizing agents into the 
direct supplying artery of the involved tumor tissue. Multiple studies have shown the procedure to alleviate 
several symptoms from patients and simultaneously improve their survival rate and quality of life. Due to its 
minimally invasive nature, TACE is only associated with severe complications in very few cases.  Finally, 
TACE has played an important role in preventing progression of liver disease in transplant candidates and 
increase their chances of receiving a new liver.  
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